Introduction
The hedgehog (Hh) gene was identified in 1980 through genetic analysis of segmentation of fruit fly Drosophila (Nusslein-Volhard and Wieschaus, 1980) . In the early 1990s, three homologs of the Hh gene were identified in vertebrates (Echelard et al., 1993; Krauss et al., 1993; Riddle et al., 1993; Chang et al., 1994; Roelink et al., 1994) . As an essential developmental signaling pathway, the Hh pathway is critical for maintaining tissue polarity and stem cell population. Inactivation of this pathway causes developmental defects such as holoprosencephaly (Bale, 2002) , whereas hyperactivation of this pathway is found in most basal cell carcinomas (BCCs) and many extracutaneous cancers (Xie, 2005; Epstein, 2008; Jiang and Hui, 2008; Xie, 2008a, c) . The emerging role of Hh signaling in human cancer further emphasizes the relevance of studying this pathway to human health.
Overall, the general signaling mechanisms of the Hh pathway is conserved from fly to the humans (Ingham and Placzek, 2006) . The seven transmembrane domain containing protein smoothened (SMO) serves as the key player for signal transduction of this pathway, whose function is inhibited by another transmembrane protein Patched (PTC) in the absence of Hh ligands. In the presence of active Hh ligands, binding of Hh to its receptor PTC releases this inhibition, allowing SMO to signal downstream, eventually leading to activation of Gli transcription factors. As transcription factors, Gli molecules can regulate target gene expression by direct association with a specific consensus sequence located in the promoter region of the target genes (Kinzler and Vogelstein, 1990; Sasaki et al., 1997) . Figure 1 shows a simplified diagram of hedgehog signaling in the presence or absence of Hh.
Signal transduction of the hedgehog pathway
Hh proteins (one Hh in Drosophila and three Hhs in mammals-Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert Hedgehog) are secreted molecules, functioning both on nearby and distant cells in developing tissues. Following translation, Hh proteins enter the secretory pathway and undergo autoprocessing and lipid modifications that produce a signaling peptide modified at its both ends by palmitoyl (N terminus) and cholesteryl (C terminus) adducts (Lee et al., 1994; Porter et al., 1995 Porter et al., , 1996 Buglino and Resh, 2008) . The movement of Hh proteins is regulated by several molecules, such as the transmembrane transporter-like protein Dispatched (Disp) (11) (12) (13) (14) and metalloproteases (Dierker et al., 2009) for release of Hh from secreting cells, the heparan sulfate proteoglycans Dally-like (Dlp) and Dally (Lum et al., 2003; Beckett et al., 2008) or their regulators (Baena-Lopez et al., 2008) for extracellular transport of Hh protein as well as enzymes such as Sulfateless and Tout velu for heparan sulfate biosynthesis (Bellaiche et al., 1998; Toyoda et al., 2000; Koziel et al., 2004) .
Patched (PTC, one PTC in fly and two PTCs in vertebrates-PTCH1 and PTCH2) is the major receptor for Hh proteins (Stone et al., 1996) . Several molecules are involved in regulation of Hh reception. Hhinteracting protein (HIP) can compete with PTC in Hh binding to inhibit Hh signaling (Chuang and McMahon, 1999) . Additional molecules, Ihog (or its vertebrate homologs CDO and BOC), GAS1 and Glypican-3, are also able to bind Hh (Okada et al., 2006; Tenzen et al., 2006; Yao et al., 2006; Zhang et al., 2006; Allen et al., 2007; Martinelli and Fan, 2007; Seppala et al., 2007; Capurro et al., 2008) although the Hh-Ihog binding mode is very different from Shh-CDO interaction (McLellan et al., 2008) . It is still not entirely clear how binding of Hh proteins results in the pathway activation. One hypothesis is that the function of SMO is normally inhibited by PTC in the absence of Hh. Binding of Hh proteins to the receptor PTC shuttles PTC out of cilium so that PTC is no longer able to inhibit SMO, leading to SMO signaling to downstream molecules.
Very little is known about signaling events immediately downstream of SMO. Although previous studies did not show direct coupling of SMO to G proteins, several recent reports support SMO-G protein coupling (Riobo et al., 2006; Molnar et al., 2007; Ogden et al., 2008; Philipp et al., 2008) . In particular, a recent study in Drosophila provides direct evidence for SMOcoupling to Gai to regulate Hh pathway activation (Ogden et al., 2008) . The physiological relevance of the G protein coupling of SMO in carcinogenesis, however, remains to be established. In Drosophila, several laboratories have shown that SMO accumulation is promoted through protein phosphorylation at the C terminus by PKA and Casein kinase I (Jia et al., 2004; Zhang et al., 2004) . SMO mutants lacking these phosphorylation sites are defective in Hh signaling. However, these phosphorylation sites are not conserved in vertebrate SMO, indicative of a different mechanism for SMO signaling in higher organisms . There are two important changes during mammalian SMO signaling. First, SMO protein undergoes conformational changes to favor intermolecular interaction of SMO (Zhao et al., 2007) . It is still not clear how this conformational change is regulated. Second, mammalian SMO protein will be translocated to cilium during Hh signaling.
Accumulating evidence from several groups indicate that the primary cilia found on most vertebrate cells have an important but undefined role in the Hh pathway (Huangfu et al., 2003; Corbit et al., 2005; Huangfu and Anderson, 2005; May et al., 2005; Zhang et al., 2005; Hoover et al., 2008) . Functions of primary cilium is regulated by large protein complexes involved in intraflagellar transport (IFT), which functions in retrograde and anterograde movement of cargo within the primary cilia (Scholey and Anderson, 2006) . A number of mutations encoding IFT proteins involved in predominantly primary cilium anterograde IFT have been described, resulting in mice with Hh loss of function phenotypes (Huangfu et al., 2003; Cortellino et al., 2009) . Several Hh components, including SMO and Gli molecules, are also present at the primary cilium upon Hh stimulation Rohatgi et al., 2009; Wang et al., 2009; Wilson et al., 2009a ). An SMO mutant lacking ciliary translocation blocks Hh signaling (Corbit et al., 2005) . Gli3 processing is significantly affected by IFT mutants (Huangfu and Anderson, 2005; May et al., 2005; Cortellino et al., 2009) , suggesting that SMO activates downstream molecules at the cilium. Current data indicate that localization of SMO to cilium is not sufficient to activate hedgehog signaling (Rohatgi et al., 2009; Wilson et al., 2009a) . Using Kif3a tissue-specific gene knockout, recent studies revealed dual roles of cilium for hedgehog signaling carcinogenesis in mouse models Wong et al., 2009) . Although Kif3a is required for SMO-mediated tumor formation, deletion of Kif3a accelerates Gli2-mediated carcinogenesis. However, it is not clear how SMO is transported to the cilium in response to Hh signaling and how SMO activates downstream effectors. One candidate molecule is b-arrestin because b-arrestin is shown to regulate ciliary localization of SMO (Kovacs et al., 2008) . The role of cilium for downstream hedgehog signaling is less clear. Two separate studies indicate that cilium is not required for Su(Fu)-mediated regulation of Gli functions Jia et al., 2009) .
There are several molecules genetically downstream of SMO signaling from Drosophila studies, including COS2 and Fused, but the functions of their vertebrate homologs in Hh signaling remains to be established. Inactivation of vertebrate homologs of COS2, KIF27 and KIF7, do not affect Hh signaling in cultured mammalian cells (Varjosalo et al., 2006) , suggesting that KIF7 and KIF27 may not be required for Hh signaling under those conditions. Recent in vivo studies support In the presence of Hh, PTC is unable to inhibit SMO. SMO undergoes conformational changes and is localized to cilium. Gli molecules are now processed to active forms (GliA), which will activate the Hh target genes. (Evangelista et al., 2008; Varjosalo et al., 2008) , but their exact functions in Hh signaling remain to be established.
The negative regulatory functions of Suppressor of Fused [Su(Fu)] in vertebrates, on the other hand, are enhanced in mammals. Su(Fu) was originally identified genetically in Drosophila by its ability to suppress active fused mutations, but is not itself required for pathway activity. Several studies suggest that Su(Fu) has a key negative regulatory role in mammalian Hh signaling. Su(Fu) null mouse mutants not only fail to repress the pathway (Svard et al., 2006) , but have some phenotypes similar to inactivation of Ptch1. Although Ptch1 þ /À mice are predisposed to developing medulloblastoma and rhabdomyosarcoma, and basal cell carcinomas following irradiation (Goodrich et al., 1997; Hahn et al., 1998; Aszterbaum et al., 1999b) , Su(fu) þ /À mice mainly develop a skin phenotype characterized by basaloid epidermal proliferations. Moreover, Su(Fu) null MEFs and wild-type cells treated with Su(Fu) siRNAs display Hh pathway activation, supporting a central role in pathway repression (Svard et al., 2006) . At the molecular level, Su(Fu) is shown to associate directly with and to inhibit Gli molecule function, and is required for Gli3 processing (Barnfield et al., 2005; Kise et al., 2009) . One potential mechanism for Hh to release the suppressing activity of Su(Fu) is accelerated Su(Fu) protein degradation upon Hh-signaling activation (Yue et al., 2009) .
Ultimately, Hh signaling is transduced to downstream Gli transcription factors, which can regulate target gene expression by a direct association with a consensusbinding site (5 0 -tgggtggtc-3 0 ) located in the promoter region of the target genes Ruppert et al., 1988; Kinzler and Vogelstein, 1990; Sasaki et al., 1997) . There are several ways to regulate the activity of Gli transcription factors. First, nuclear-cytoplasmic shuttling of Gli molecules is tightly regulated (Kogerman et al., 1999; Barnfield et al., 2005; Sheng et al., 2006; Stecca et al., 2007) . For example, protein kinase A is shown to retain Gli1 proteins in the cytoplasm (through a PKA site in the nuclear localization signal peptide) whereas active Ras signaling promotes Gli nuclear localization (Stecca et al., 2007) . Second, ubiquitination and protein degradation of Gli molecules is also regulated by several distinct mechanisms, including b-TRCP-, cul3/BTBand numb/Itch-mediated Gli ubiquitination (Di Marcotullio et al., 2006; Huntzicker et al., 2006; Jiang, 2006; Pan et al., 2006; Wang and Li, 2006) . In addition to protein degradation, Gli3 and (Gli2 to a less extent) can be processed into transcriptional repressors, which may be mediated by the b-TRCP E3 ligase (Wang and Li, 2006) . Defects in the retrograde motor for IFT are also shown to affect Gli3 processing (Huangfu and Anderson, 2006) . Fourth, transcriptional activity of Gli molecules is also tightly regulated. Su(Fu) not only prevents nuclear translocation of Gli molecules, but also inhibits Gli1-mediated transcriptional activity (Cheng and Bishop, 2002) . Table 1 summarizes major components of the Hh pathway in vertebrates.
There are several feedback regulatory loops in this pathway. PTC, HIP, GAS1 and Gli1, which are components of this pathway, are also the target genes. PTC and HIP provide negative feedback mechanisms to maintain the pathway activity at an appropriate level in a given cell. In contrast, Gli1 forms a positive regulatory loop. GAS1, on the other hand, is downregulated by the HH pathway, but it is positively involved in Hh signaling. Alteration of these loops is expected to result in abnormal signaling of this pathway, such as loss of PTCH1 in BCCs.
Activation of the hedgehog pathway in human cancer
Hedgehog signaling, gorlin syndrome and BCCs The major breakthrough in our understanding of Hh signaling in human cancers came from the discovery that mutations of human homolog of the drosophila patched gene (PTCH1) are associated with a rare hereditary form of BCC-Basal Cell Nevus Syndrome (also called Gorlin syndrome) (Hahn et al., 1996; Johnson et al., 1996; Epstein, 2001) . Gorlin syndrome has a high risk of BCCs and an increased risk of medulloblastomas. Indeed, mutations of PTCH1 have been found in both sporadic BCCs and medulloblastomas. The tumor suppressor role of PTCH1 has been further shown in mice. Mice heterozygous for a Ptch1 null mutation show the essential features in basal cell nevus syndrome patients, such as tumor development such as (medulloblastomas, rhabdomyosarcomas and BCCs) and developmental defects (such as spina bifida occulta) (Goodrich et al., 1997; Hahn et al., 1998; Aszterbaum et al., 1999a) . In human organotypic skin cultures, keratinocytes with heterozygous mutation of PTCH1 show high invasiveness, hyperproliferation and Hedgehog signaling in human cancer L Yang et al marked differentiation impairment in comparison with wild-type keratinocytes, arguing for PTCH1 haploinsufficiency in cancer development (Brellier et al., 2008) . BCC, the most common human cancer consistently has abnormalities of the hedgehog pathway with PTCH1 mutations in 50% human sporadic BCCs, suggesting alteration of additional genes in the hedgehog pathway in this type of skin cancer. Indeed, mutations of SMO are found in about 10% of sporadic BCCs (Reifenberger et al., 1998 (Reifenberger et al., , 2005 Xie et al., 1998; Lam et al., 1999; Couve-Privat et al., 2002) . Unlike wildtype SMO, expression of activated SMO molecules in mouse skin results in formation of BCC-like tumors (Xie et al., 1998) . It is also reported that SU(FU) is mutated in a small number of BCCs (Reifenberger et al., 2005) . Taking all the mutation data into account, there are still about 30% of BCCs without the underlying molecular basis for the activated hedgehog signaling. Thus, we predict that mutations of additional genes in the hedgehog pathway are yet to be discovered in sporadic BCCs. Molecular studies indicate that activated hedgehog signaling in BCCs, leads to cell proliferation through elevated expression of PDGFRa (Xie et al., 2001) , whereas targeted inhibition of hedgehog signaling causes apoptosis via Fas induction (Athar et al., 2004) .
Activation of Hh signaling in extracutaneous tumors
In addition to tumors associated with Gorlin syndrome, recent studies indicate that Hh signaling is activated in many extracutaneous tumors, including brain tumors, gastrointestinal, prostate, lung and breast cancers. Unlike the situation in BCCs and meduloblastomas, gene mutation is not primarily responsible for activated Hh signaling in these tumors Watkins et al., 2003) . There is evidence to indicate ligand-dependent growth in most extracutaneous cancers. However, there are variations from one study to another as to the frequency of ligand-dependence vs ligand-independence in a given tumor. This could be due to the size of samples, methods used in the study or even the type of samples. Studies also indicate that Hh signaling may be involved in different stages of carcinogenesis in different tumors. In pancreatic and esophageal cancers for example, activation of this pathway is found in both early tumors and metastatic cancer (Bailey et al., 2009; Feldmann et al., 2008; Ma et al., 2006; Pasca di Magliano and Hebrok, 2003) , suggesting that Hh signaling has a significant role in carcinogenesis of these tumors. In support of these findings, transgenic mice with pancreatic-specific expression of SHH or (Sheng et al., 2004) . The latter often contains less than 10% of tumor mass in the tissue. Third, different standards have been used to define Hh signaling activation. Some groups use elevated expression of Gli1 as the read-out of Hhsignaling activation (Stecca et al., 2007; Bhattacharya et al., 2008) whereas others assess expression of several Hh target genes, such as Gli1, PTCH1, sFRP1 and HIP (Thayer et al., 2003; Karhadkar et al., 2004; Ma et al., 2005; Huang et al., 2006; Lee et al., 2007) . Similarly, some groups use only immunohistochemistry to detect Hh-signaling activation (Kubo et al., 2004; Liao et al., 2009 ) whereas most studies use multiple approaches. As the research in this area progresses, we will see a better picture about Hh-signaling activation in human cancer.
It is worth pointing out that correlation of hedgehog target gene expression with tumor specimens is not sufficient to claim a role of hedgehog signaling in a given cancer type. Establishing animal models using tissuespecific activation of Hh signaling is critical for understanding the role of Hh signaling in carcinogenesis. For example, it was shown in orthotopic mouse models that hedgehog signaling is required for tumor metastasis of pancreatic cancer ( (Feldmann et al., 2007) and our unpublished data). In contrast, pancreatic-specific deletion of Smo did not affect PDA formation whereas GLI2 expression resulted in undifferentiated pancreatic tumors (Morton et al., 2007; Nolan-Stevaux et al., 2009 ). These studies indicate that activation of hedgehog signaling is not sufficient for tumor formation of PDAC. The role of Hh signaling in medulloblastomas is also clearly shown in animal models. For example, specific expression of active SMO, SmoM2, in mouse cerebellar granule neuron precursors (ND2:SmoA1 mice) results in formation of medulloblastomas (Hatton et al., 2008) .
The modes of hedgehog signaling in cancer development may vary from one tumor type to another in extracutaneous cancers. Recent reports indicate that paracrine hedgehog signaling has an important role in carcinogenesis (Dierks et al., 2007; Yauch et al., 2008; Nolan-Stevaux et al., 2009; Tian et al., 2009) . As a recent review has detailed these studies, we will not repeat here. In the paracrine-signaling model, Shh or Ihh ligands secreted by the tumor cells activate hedgehog signaling in the stromal cells. A study in B-cell lymphomas proposes a different paracrine Hh signaling (Dierks et al., 2007; Lindemann, 2008) in which Shh is secreted by the stromal cells to activate the hedgehog pathway in the cancer cells. In the orthotopic model of pancreatic cancer, we observed both paracrine and autocrine hedgehog signaling (our unpublished data). A thorough analysis of hedgehog target gene expression in human pancreatic tumors using in situ hybridization and immunohistochemistry will help clarify the issue. Further studies are clearly needed to identify the component(s) in the stroma of a particular tumor type and tumor stage responsive to hedgehog signaling.
Mounting evidence indicate that hedgehog signaling is required for maintenance of cancer stem cell population (Dierks et al., 2008; Read et al., 2009; Zhao et al., 2009 ). For example, recent studies indicate that leukemia stem cells maintenance and expansion is dependent on hedgehog signaling (Dierks et al., 2008; Zhao et al., 2009) . In the absence of Smo or treatment of cyclopamine, the hematopoietic stem cell population is dramatically reduced. Based on cancer stem cell theory, one would anticipate that Hh-signaling activation may exert chemotherapy or radiotherapy resistance in cancer if this pathway has a major role in cancer stem cell functions (Reya et al., 2001) . Several studies have shown that Hh-signaling activation is associated with chemotherapy resistance or radiotherapy resistance (Sims-Mourtada et al., 2006; Yoshikawa et al., 2008; Olive et al., 2009) , supporting that hedgehog signaling activation has a role in cancer stem cell functions. It was recently reported that Hh-signaling inhibitor enhances the delivery of chemotherapy in a mouse model of pancreatic cancer (Olive et al., 2009) . Despite all these progresses, more experiments are needed to determine whether Hh signaling is important for cancer stem cells in solid tumors.
Interactions between hedgehog signaling and other pathways
Major advances have been made in understanding the interactions between Hh signaling and other pathways during carcinogenesis. Figure 2 is a summary of recent findings on pathway cross talks. In most studies, the interaction between hedgehog signaling and another pathway is established with little molecular mechanisms. In several cases, the regulation mechanism is known. Koga et al., 2008; Kasperczyk et al., 2009) . Expression of Gli1 is reported to be regulated by TGFb, Ras, JUN, SCL/TAL1 and EWS-FLI1 oncoprotein (Ji et al., 2007; Kasai et al., 2008; Zwerner et al., 2008; Beauchamp et al., 2009; Laner-Plamberger et al., 2009; NolanStevaux et al., 2009) . The interaction between PKC and hedgehog signaling varies depending on PKC isoforms and cell types. Although PKCa is shown to activate hedgehog signaling, PKC delta inhibits hedgehog signaling (Cai et al., 2009 ).
Significant progress has been made in the cross talk between Hh signaling and p53, wnt and growth factors in cancer. Hh and wnt signaling can form a positive feedback loop or a negative feedback loop depending on tissue context. On the one hand, Hh signaling can exert negative effects on wnt signaling through elevated expression of wnt signaling inhibitor sFRP-1 in gastric cancer Yanai et al., 2008) . On the other hand, Hh-mediated skin carcinogenesis requires the wnt pathway (Yang et al., 2008) . The p53 pathway and Hh signaling are two major alterations in BCCs and medulloblastomas, leading to speculation that the p53 pathway collaborates with Hh signaling in carcinogenesis. Indeed, almost all Ptch1 þ /À mice in p53 null background develop medulloblastomas, BCCs and other tumor types whereas Ptch1 þ /À mice in p53 wildtype background have a low frequency of tumor development (Romer et al., 2004; Epstein, 2008) . Recent studies reveal that Hh signaling overrides p53-mediated signaling through regulation of MDM2, and p53 negatively regulates Gli1 expression (Abe et al., 2008; Stecca and Ruiz i Altaba, 2009 ). This feedback regulatory loop seems to be required for maintaining stem cell number and cancer cell number. Several hedgehog target genes are growth factors or growth factor receptors (Xie, 2008b) , such as IGF-2, VEGF and PDGFRa. Recent data further show the significance of IGF signaling for Hh-mediated carcinogenesis (Corcoran et al., 2008; Parathath et al., 2008) . Gene expression analysis in keratinocytes indicates that EGF and hedgehog have synergistic effects on gene expression of MEK/ERK/JUN (Kasper et al., 2006; Schnidar et al., 2009) . There is a hope that inhibition of Hh signaling and growth factor pathways will result in better treatment of cancer (Shaw and Prowse, 2008) .
Small-molecule modulators of hedgehog signaling
Over 50 compounds have been disclosed to have inhibitory effects on hedgehog signaling. Among these compounds, five have been used in clinical trials. Hh-signaling inhibitors identified so far are mainly targeted to three sites in the Hh pathway: Ligand Hh molecules (Shh-neutralizing antibodies, Robotnikinin); SMO protein (cyclopamine and its derivatives IPI-926, Cyc-T and synthetic compounds GDC-0449, Cur61414, XL-139 and LDE-225); and Gli inhibitors (HPI-1, HPI-2, GANT-56 and GANT-61). Over the 50 disclosed compounds, five have gone to clinical trials, including GDC-0449, XL-139, IPI-926 and LDE-225. These compounds can be divided into three groups: natural products (cyclopamine its derivatives and other natural products); novel synthetic compounds and Hh-signaling modulators.
Natural products (cyclopamine, its derivatives and others) Cyclopamine, a plant-derived steroidal alkaloid, binds directly to the transmembrane helices of SMO and inhibits Hh signaling (Chen et al., 2002a) . The discovery of small-molecule antagonists of SMO such as cyclopamine has opened up exciting new prospects for molecularly targeted therapy and prevention for human cancers associated with Hh signaling. Several other natural products were also shown to have inhibitory activities to Hh signaling, but the in vivo data using these compounds are not available Hosoya et al., 2008) . Results generated from in vitro studies using cyclopamine are often not consistent. Although cyclopamine has some specificity to Hh signaling at a low concentration (o10 mM), overdose of cyclopamine can cause cell death without affecting Hh signaling (Yauch et al., 2008) . Although the control for cyclopamine treatment is hard to find, tomatidine has been used as a control in Hedgehog signaling in human cancer L Yang et al many studies (Karhadkar et al., 2004; Huang et al., 2006; Liao et al., 2009) . If the cyclopamine effect is specific, overexpression of the downstream transcription effector (Gli1 or Gli2) in the sensitive cells should render the cells resistant to cyclopamine (Ma et al., 2005) . As increasing evidence indicates that Hh signaling requires stromal components in human cancers, in vitro studies on Hh signaling in human cancer should be backed up with in vivo data. Despite the concerns of off target effects of cyclopamine in cultured cells, the in vivo effect of cyclopamine on tumor shrinkage has been shown in several mouse models. Oral cyclopamine can block the growth of UV-induced BCCs in Ptch1 þ /À mice by 50%, perhaps by increasing Fas-induced apoptosis (Athar et al., 2004) . Cyclopamine treatment in this mouse model prevents formation of additional microscopic BCCs, implying a potential use of cyclopamine for BCC prevention. Cyclopamine administration reduced BCCs, but not SCCs or fibrosarcomas in these mice, highlighting the specificity of cyclopamine for the hedgehog pathway (Athar et al., 2004) . Similarly, cyclopamine is effective in reducing medulloblastoma development in Ptch1 þ /À mice (Sanchez and Ruiz i Altaba, 2005) as well as tumor growth of many cancer cell lines in nu/nu mice (Berman et al., 2002; Thayer et al., 2003; Karhadkar et al., 2004; Stecca et al., 2007) . More improved cyclopamine derivatives that have significantly increased the acid stability and aqueous solubility are now available, such as IPI-926 and Cyc-T (Tremblay et al., 2009 (Hyman et al., 2009; Rudin et al., 2009; Von Hoff et al., 2009 (Williams et al., 2003) . Since then, a topical formulation of this compound was tested against sporadic BCCs in a Phase I clinical trial. However, this clinical trial failed to show the effects on Hh target gene expression by the compound (Scales and de Sauvage, 2009 ). In addition, several other synthetic compounds have been identified to bind directly to SMO but with no structural similarity to cyclopamine (Frank-Kamenetsky et al., 2002; Chen et al., 2002b) . Four of these compounds are now in clinical trials including GDC-0449. The successful clinical trials with GDC-0449 on human BCCs further encourage the translational studies in this area (Von Hoff et al., 2009) (Table 2 ). Another clinical trial of GDC-0449 on a medulloblastoma patient also resulted in a rapid reduction of tumor (although transiently) but the drug resistance occurred because of SMO mutation Rudin et al., 2009) . Recent results from mouse models indicate that the inhibition of Hh signaling has little effects on bone barrow stem cell population, which clears the concern of toxic effects of Hh signaling inhibition on normal stem cells Hofmann et al., 2009) .
Based on diversity-oriented synthesis and smallmolecule microarrays, a small-molecule robotnikinin is reported to bind Shh protein and blocks Shh signaling in cell lines, human primary keratinocytes and a synthetic model of human skin (Stanton et al., 2009) . Robotnikinin inhibits Shh signaling in a concentrationdependent manner but shows no inhibitory activity in a cell line lacking the Ptc1 receptor, does not compete with cyclopamine-Smo interactions and does not show an inhibitory effect in the presence of the well- (Stanton et al., 2009) . A few small-molecule inhibitors for Gli1 functions are identified through chemical library screening (Lauth et al., 2007; Hyman et al., 2009) . Importantly, the discovered compounds efficiently inhibited in vitro tumor cell proliferation in a GLI-dependent manner and successfully blocked cell growth in an in vivo xenograft model using human prostate cancer cells harboring downstream activation of the Hh pathway (Lauth et al., 2007) . The growth of these tumors cannot be inhibited by cyclopamine or its analogs, raising the possibility that these Hh antagonists may have broad uses in cancer therapeutics. These antagonists targeting Hh downstream effectors constitute a valuable set of chemical tools for developing chemotherapies against Hh pathway-related cancers.
Other Hh-signaling modulators Recent studies indicate that vitamin D3, the secretion of which can be facilitated by PTCH1, can inhibit SMO signaling through direct binding to SMO. This finding raises a possibility to treat BCCs with nutrition supplements (Bijlsma et al., 2006) . Promising data show that the effect of tazarotene, a retinoid with retinoic acid receptor b/g specificity against BCC carcinogenesis is sustained after its withdrawal (So et al., 2008) .
As abnormal expression of Shh is very common in several human cancer types, neutralizing antibodies for Shh show effectiveness in reducing cell proliferation in cancer cells with activated Hh signaling . Shh-neutralizing antibodies are quite promising in future treatment of Hh signaling-dependent cancers.
In addition, several synthetic SMO agonists are available for functional studies of Hh signaling in human cancer (Frank-Kamenetsky et al., 2002) . With appropriate optimization, it is possible that these Hh agonists may be used to treat human conditions with reduced Hh signaling, such as holoprosencephaly. Table 2 shows the current small-molecule inhibitors of Hh signaling.
Summary
In summary, rapid advancement in our understanding of Hh signaling has provided great opportunities for developing novel therapeutic strategies for human cancer with activated Hh signaling. Optimized use of Hh-signaling antagonists will make the novel cancer therapeutics feasible. The challenges for therapeutic application of Hh-signaling inhibitors include identification of the right tumors for therapeutic application, reliable and reproducible animal models for testing these compounds and optimization of drug dosages to minimize the side effects.
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